Â SM-88 OS trend is encouraging in this poor prognosis patient population. Â Several encouraging efficacy markers (reduction in CTCs; achieving SD or better) correlate with greater survival.
Â Further investigation will be conducted into the prognostic indicators associated with longer survival. Â SM-88 was well tolerated. Â Further SM-88 pivotal trials in pancreatic cancer are planned as well as evaluation in other tumor types. 
INTRODUCTION BACKGROUND METHODS
Â TYME conducted a multi-center*, open-label, dose optimization randomized Phase II trial evaluating SM-88 in advanced Pancreatic Ductal Adenocarcinoma (PDAC).
Â SM-88 is the lead investigational therapy in the TYME Cancer Metabolism Based Therapies (CMBTs TM ) platform. SM-88 is an oral modified dysfunctional tyrosine that is hypothesized to disrupt cancer cell metabolism.
Â SM-88 has demonstrated encouraging efficacy and a well-tolerated safety profile in 15 different tumor types, including solid tumors and hematologic malignancies across four separate studies. Â The median percentage decrease of CTCs is 63%.
CIRCULATING TUMOR CELLS (CTCs) AND OVERALL SURVIVAL OVERALL SURVIVAL BASELINE PROGNOSTIC INDICATORS ASSOCIATED WITH SHORTENED SURVIVAL
Â 56.3% (9/16) patients with CTC decreases had OS of at least 180 days vs. 37.5% (3/8) of patients with CTC increases.
Â Patients who had at least an 80% CTC reduction trended towards greater survival.
Â Patients with ≤ 50 cells/4mL at nadir trended towards greater survival.
Figure 6c
Best CTC Response by Absolute Number > 50 Cells/4mL ≤ 50 Cells/4mL
